Bruseo CW - Search Results

1

CGS 34226, a thiol-based dual inhibitor of endothelin converting enzyme-1 and neutral endopeptidase 24.11.

Jeng AY, Savage P, Beil ME, Bruseo CW, Hoyer D, Fink CA, Trapani AJ. Jeng AY, et al. Among authors: bruseo cw. Clin Sci (Lond). 2002 Aug;103 Suppl 48:98S-101S. doi: 10.1042/CS103S098S. Clin Sci (Lond). 2002. PMID: 12193064

2

Effects of the ECE/NEP inhibitor CGS 34225 on the big ET-1-induced pressor response and plasma atrial natriuretic peptide concentration in conscious rats.

Trapani AJ, Beil ME, Bruseo CW, Fink CA, Hoyer D, Savage P, Jeng AY. Trapani AJ, et al. Among authors: bruseo cw. Clin Sci (Lond). 2002 Aug;103 Suppl 48:102S-106S. doi: 10.1042/CS103S102S. Clin Sci (Lond). 2002. PMID: 12193065

3

Synthesis and biological activity of potent heterocyclic thiol-based inhibitors of endothelin-converting enzyme-1.

Firooznia F, Gude C, Chan K, Tan J, Fink CA, Savage P, Beil ME, Bruseo CW, Trapani AJ, Jeng AY. Firooznia F, et al. Among authors: bruseo cw. Bioorg Med Chem Lett. 2002 Nov 4;12(21):3059-62. doi: 10.1016/s0960-894x(02)00683-2. Bioorg Med Chem Lett. 2002. PMID: 12372501

4

CGS 35601 and its orally active prodrug CGS 37808 as triple inhibitors of endothelin-converting enzyme-1, neutral endopeptidase 24.11, and angiotensin-converting enzyme.

Trapani AJ, Beil ME, Bruseo CW, Savage P, Firooznia F, Jeng AY. Trapani AJ, et al. Among authors: bruseo cw. J Cardiovasc Pharmacol. 2004 Nov;44 Suppl 1:S211-5. doi: 10.1097/01.fjc.0000166237.57077.d6. J Cardiovasc Pharmacol. 2004. PMID: 15838282

5

CGS 34043: a non-peptidic, potent and long-acting dual inhibitor of endothelin converting enzyme-1 and neutral endopeptidase 24.11.

Trapani AJ, De Lombaert S, Beil ME, Bruseo CW, Savage P, Chou M, Jeng AY. Trapani AJ, et al. Among authors: bruseo cw. Life Sci. 2000;67(9):1025-33. doi: 10.1016/s0024-3205(00)00695-0. Life Sci. 2000. PMID: 10954036

6

Design and synthesis of a potent and selective endothelin-converting enzyme inhibitor, CGS 35066.

Jeng AY, De Lombaert S, Beil ME, Bruseo CW, Savage P, Chou M, Trapani AJ. Jeng AY, et al. Among authors: bruseo cw. J Cardiovasc Pharmacol. 2000 Nov;36(5 Suppl 1):S36-9. doi: 10.1097/00005344-200036051-00014. J Cardiovasc Pharmacol. 2000. PMID: 11078330

7

Pharmacological properties of CGS 35066, a potent and selective endothelin-converting enzyme inhibitor, in conscious rats.

Trapani AJ, Beil ME, Bruseo CW, De Lombaert S, Jeng AY. Trapani AJ, et al. Among authors: bruseo cw. J Cardiovasc Pharmacol. 2000 Nov;36(5 Suppl 1):S40-3. doi: 10.1097/00005344-200036051-00015. J Cardiovasc Pharmacol. 2000. PMID: 11078331

8

Synthesis and biological activity of novel potent endothelin-converting enzyme-1 inhibitors.

Firooznia F, Gude C, Chan K, Fink CA, Qiao Y, Satoh Y, Marcopoulos N, Savage P, Beil ME, Bruseo CW, Trapani AJ, Jeng AY. Firooznia F, et al. Among authors: bruseo cw. Bioorg Med Chem Lett. 2001 Feb 12;11(3):375-8. doi: 10.1016/s0960-894x(00)00657-0. Bioorg Med Chem Lett. 2001. PMID: 11212114

9

Dipeptide sulfonamides as endothelin ETA/ETB receptor antagonists.

Ksander GM, Shetty SS, DelGrande D, Balwierczak JL, Bruseo CW, Savage P, deJesus R, Yuan A, Webb RL, Jeng AY. Ksander GM, et al. Among authors: bruseo cw. Can J Physiol Pharmacol. 2002 May;80(5):464-9. doi: 10.1139/y02-028. Can J Physiol Pharmacol. 2002. PMID: 12056554

10

Characterization of a potent and selective endothelin-B receptor antagonist, IRL 2500.

Balwierczak JL, Bruseo CW, DelGrande D, Jeng AY, Savage P, Shetty SS. Balwierczak JL, et al. Among authors: bruseo cw. J Cardiovasc Pharmacol. 1995;26 Suppl 3:S393-6. J Cardiovasc Pharmacol. 1995. PMID: 8587424

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

13 results

Search Page

Filters